EGM
CRSP icon

Engineers Gate Manager’s CRISPR Therapeutics CRSP Stock Holding History

Engineers Gate Manager’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Buy
+10,730
New +$566K 0.01% 1413
2026
Q1 		– Sell
-25,950
Closed -$1.36M – 2245
2025
Q4 		$1.36M Buy
+25,950
New +$1.55M 0.02% 888
2025
Q3 		– Sell
-16,643
Closed -$810K – 2227
2025
Q2 		$810K Sell
16,643
-2,703
-14% -$105K 0.01% 1228
2025
Q1 		$658K Buy
19,346
+9,176
+90% +$389K 0.01% 1309
2024
Q4 		$400K Buy
+10,170
New +$480K 0.01% 1568
2024
Q3 		– Sell
-30,982
Closed -$1.67M – 2165
2024
Q2 		$1.67M Buy
30,982
+10,062
+48% +$582K 0.04% 646
2024
Q1 		$1.43M Buy
20,920
+15,952
+321% +$1.14M 0.04% 635
2023
Q4 		$311K Sell
4,968
-426
-8% -$23.6K 0.01% 1434
2023
Q3 		$245K Buy
+5,394
New +$279K 0.01% 1410
2023
Q1 		– Sell
-9,935
Closed -$404K – 1706
2022
Q4 		$404K Buy
+9,935
New +$527K 0.02% 1028
2022
Q3 		– Sell
-17,513
Closed -$1.06M – 1694
2022
Q2 		$1.06M Sell
17,513
-1,348
-7% -$79.2K 0.04% 670
2022
Q1 		$1.18M Buy
18,861
+8,951
+90% +$562K 0.05% 554
2021
Q4 		$751K Buy
9,910
+6,884
+227% +$601K 0.03% 772
2021
Q3 		$339K Sell
3,026
-1,754
-37% -$220K 0.02% 1118
2021
Q2 		$774K Buy
+4,780
New +$581K 0.05% 557
2020
Q2 		– Sell
-20,510
Closed -$870K – 1736
2020
Q1 		$870K Buy
20,510
+9,621
+88% +$497K 0.06% 499
2019
Q4 		$663K Sell
10,889
-112
-1% -$6.12K 0.03% 845
2019
Q3 		$451K Buy
+11,001
New +$526K 0.02% 830

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Engineers Gate Manager's CRSP Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10,730 shares worth $585K. The stake represents 0.01% of the portfolio and ranks #1413 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in CRSP as recently as Q4 2025.

Engineers Gate Manager first reported a position in CRSP in Q3 2019 and has held it in 18 quarters since. The position peaked at $1.67M in Q2 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Engineers Gate Manager held 10,730 shares of CRISPR Therapeutics worth $585K as of Q2 2026.
  • CRISPR Therapeutics was a new Engineers Gate Manager position in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1413 holding.
  • Engineers Gate Manager first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • Engineers Gate Manager's CRISPR Therapeutics position peaked at $1.67M in Q2 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.